Changes in the concentrations of dopamine (DA) and its major metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), were characterized in the pituitary gland throughout the 4-day estrous cycle of the rat. Female rats were sacrificed at 2- to 3-hour intervals throughout each day of the 4-day estrous cycle. Pituitary glands were removed, and the concentrations of DA and DOPAC were determined by high-performance liquid chromatography coupled to electrochemical detection. The concentration of prolactin (PRL) in serum from these same animals was determined by radioimmunoassay. The concentration of DA in the anterior lobe was constant throughout most of the 4-day estrous cycle. Prior to initiation of the proestrous surge of PRL, there were significant (p <0.05) decreases in the concentrations of both DA and DOPAC in the anterior lobe which returned to elevated baseline levels just prior to the termination of the proestrous surge of PRL. The concentrations of DA and DOPAC in the intermediate lobe exhibited a daily rhythm. However, in the intermediate as well as in the anterior lobe, there were significant (p < 0.001) decreases in the concentrations of both DA and DOPAC, coincident with the initiation of the proestrous surge of PRL. Similarly, coincident with the peak of the proestrous surge of PRL, there were significant (p < 0.001) increases in the concentrations of DA and DOPAC in the intermediate lobe, followed by a return to basal levels and resumption of the daily rhythm. The pattern of the concentrations of DA and DOPAC in the neural lobe was also daily in nature, with peaks occurring between 13.00 and 15.00 h each day of the 4-day estrous cycle. These data, taken together: (1) confirm that a decrease of the concentrations of DA and DOPAC occurs in the anterior lobe prior to the proestrous surge of PRL; (2) reveal that DA is released in a daily pattern at intermediate and neural lobes, and (3) suggest an apparent role for DA released to the intermediate lobe in the regulation of the proestrous surge of PRL.

Keywords:
Catecholamines, Prolactin, Estrous cycle, Rhythms
1.
Ben-Jonathan N: Dopamine: A prolactin-inhibiting hormone. Endocr Rev 1985;6:564–589.
2.
Fuxe K: Cellular locdalization of monoamines in the median eminence and in the infundibular stem of some mammals. Acta Physiol Scand 1963;58:383–384.
3.
Bjorklund A, Moore RY, Nobin A, Stenevi U: The organization of tubero-hypophysical and reticulo-infundibular catecholamine neuron systems in the rat brain. Brain Res 1973;51:171–191.
4.
Goudreau JL, Falls WM, Lookingland KJ, Moore KE: Periventricular-hypophysical dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Neuronedocrinology 1995;62:147–154.
5.
Goudreau JL, Lindley SE, Lookingland KJ, Moore KE: Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary. Neuroendocrinology 1992;56:100–105.
6.
Mulchahey JJ, Neill JD: Dopamine levels in the anterior pituitary gland monitored by in vivo electrochemistry. Brain Res 1986;386:332–340.
7.
Lookingland KJ, Jarry HD, Moore KE: The metabolism of dopamine in the median eminence reflects the activity of tuberoinfundibular neurons. Brain Res 1987;419:303–310.
8.
Lindley SE, Gunnet JW, Lookingland KJ, Moore KE: 3,4-Dihydroxyphenylacetic acid concentrations in the intermediate lobe and neural lobe of the posterior pituitary gland as an index of tuberohypophysial dopaminergic neuronal activity. Brain Res 1990;506:133–138.
9.
Kerdelhue B, Bojda F, Lesieur P, Pasqualini C, El Abed A, Lenoir V, Douillet P, Chiueh MC, Palkovits M: Median eminence dopamine and serotonin neuronal activity: Temporal relationship to preovulatory prolactin and luteinizing hormone surges. Neuroendocrinology 1989;49:176–180.
10.
Ahren K, Fuxe H, Hamberger L, Hökfelt T: Turnover changes in the tubero-infundibular dopamine neurons during the ovarian cycle of the rat. Endocrinology 1971;88:1415–1424.
11.
Demarest KT, Riegle GD, Moore KE: Adenohypophysial dopamine content during physiological changes in prolactin secretion. Endocrinology 1984;115:2091–2097.
12.
Chiocchio SR, Chafuen S, Tramezzani JH: Changes in adenohypophysial dopamine related to prolactin release. Endocrinology 1980;106:1682–1685.
13.
Murai I, Ben-Jonathan N: Chronic posterior pituitary lobectomy: Prolonged elevation of plasma prolactin and interruption of cyclicity. Neuroendocrinology 1986;43:453–458.
14.
Arbogast LA, Murai I, Ben-Jonathan N: Differential alterations in dopamine turnover rates in the stalk-median eminence and posterior pituitary during the preovulatory prolactin surge. Neuroendocrinology 1989;49:525–530.
15.
Murai I, Reichlin S, Ben-Jonathan N: The peak phase of the proestrous prolactin surge is blocked by either posterior pituitary lobectomy or antisera to vasoactive intestinal peptide. Endocrinology 1989;124:1050–1055.
16.
Freeman ME, Sterman JR: Ovarian steroid modulation of prolactin surges in cervically stimulated ovariectomized rats. Endocrinology 1978;102:1915–1920.
17.
Carr LA, Voogt JL: Catecholamine synthesizing enzymes in the hypothalamus during the estrous cycle. Brain Res 1980;196:437–445.
18.
Lerant A, Freeman ME: Dopaminergic neurons in periventricular and arcuate nuclei of proestrous and ovariectomized rats: Endogenous diurnal rhythm of Fos-related antigen expression. Neuroendocrinology 1997;65:436–445.
19.
Demarest KT, Moore KE, Riegle GD: Adenohypophysial dopamine content and prolactin secretion in the aged male and female rat. Endocrinology 1985;116:1316–1323.
20.
Jones EE, Naftolin F: Estrogen effects on the tuberoinfundibular dopaminergic system in the female rat brain. Brain Res 1990;510:84–91.
21.
Pasqualini C, Leviel V, Guibert B, Faucon Biguet N, Kerdelhue B: Inhibitory actions of acute estradiol treatment on the activity and quantity of tyrosine hydoxylase in the median eminence of ovariectomized rats. J Neuroendocrinol 1991;3:575–580.
22.
Blum M, McEwen BS, Roberts JL: Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. J Biol Chem 1987;262:817–821.
23.
Morrell JI, Rosenthal MF, McCabe JT, Harrington CA, Chikaraishi DM, Pfaff DW: Tyrosine hydroxylase mRNA in the neurons of the tuberoinfundibular region and zona incerta examined after gonadal steroid hormone treatment. Mol Endocrinol 1989;3:1426–1433.
24.
Foreman MM, Porter JC: Prolactin augmentation of dopamine and norepinephrine release from superfused medial basal hypothalamic fragments. Endocrinology 1981;108:800–804.
25.
Gudelsky GA, Porter JC: Release of dopamine from tuberoinfundibular neurons into pituitary stalk blood after prolactin or haloperidol administration. Endocrinology 1980;106:526–529.
26.
Toney TW, Pawsat DE, Fleckenstein AE, Lookingland KJ, Moore KE: Evidence that prolactin mediates the stimulatory effects of estrogen on tuberoinfundibular dopamine neurons in female rats. Neuroendocrinology 1992;55:282–289.
27.
Hökfelt T, Fuxe K: Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons. Neuroendocrinology 1972;9:100–122.
28.
Annunziato L, Moore KE: Prolactin in CSF selectively increases dopamine turnover in the median eminence. Life Sci 1978;22:2037–2041.
29.
Lookingland KJ, Jarry HD, Moore KE: The metabolism of dopamine in the median eminence reflects the activity of tuberoinfundibular neurons. Brain Res 1987;419:303–310.
30.
Barden N, Chevillard C, Saavedra JM: Diurnal variations in rat posterior pituitary catecholamine levels. Neuroendocrinology 1982;34:148–150.
31.
Banns H, Blatchford D, Godden U, Holzbauer M, Mann SP, Sharman DF: Pituitary dopamine in rats after decreased water intake. Br J Pharmacol 1978;62:462.
32.
Holzbauer M, Sharman DF, Godden U: Observations on the function of the dopaminergic nerves innervating the pituitary gland. Neuroscience 1978;3:1251–1262.
33.
Alper RH, Demarest KT, Moore KE: Dehydration selectively increases dopamine synthesis in tuberohypophyseal dopaminergic neurons. Neuroendocrinology 1980;31:112–115.
34.
Tarttelin MF, Gorski RA: Variations in food and water intake in the normal and acyclic female rat. Physiol Behav 1971;7:847–852.
35.
Arey BJ, Averill RL, Freeman ME: A sex-specific endogenous stimulatory rhythm regulating prolactin secretion. Endocrinology 1989;124:119–123.
36.
Annunziato L, Weiner RI: Characteristics of dopamine uptake and 3,4-dihydroxyphenylacetic acid (DOPAC) formation in the dopaminergic terminals of the neurointermediate lobe of the pituitary gland. Neuroendocrinology 1980;31:8–12.
37.
Demarest KT, Moore KE: Lack of a high affinity transport system for dopamine in the median eminence and posterior pituitary. Brain Res 1979;171:545–551.
38.
Hill JB, Lacy ER, Nagy GM, Görcs TJ, Frawley LS: Does α-melanocyte-stimulating hormone from the pars intermedia regulate suckling-induced prolactin release? Supportive evidence from morphological and functional studies. Endocrinology 1993;133:2991–2997.
39.
Rivier C, Vale W, Ling N, Brown M, Guillemin R: Stimulation in vivo of the secretion of prolactin and growth hormone by beta-endorphin. Endocrinology 1977;100:238–241.
40.
Loeffler JP, Demeneix BA, Kley NA, Höllt V: Dopamine inhibition of proopiomelanocortin gene expression in the intermediate lobe of the pituitary: Interactions with corticotropin-releasing factor and the beta-adrenergic receptors and the adenylate cyclase system. Neuroendocrinology 1988;47:95–101.
41.
Lindley SE, Gunnet JW, Lookingland KJ, Moore KE: Effects of alterations in the activity of tuberohypophysial dopaminergic neurons on the secretion of alpha-melanocyte stimulating hormone. Proc Soc Exp Biol Med 1988;188:282–286.
42.
Vermes I, Tilders FJH, Stoof JC: Dopamine inhibits the release of immunoreactive beta endorphin from rat hypothalamus in vitro. Brain Res 1985;326:41–46.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.